Agile Therapeutics, Inc. Announces Management Changes
July 06, 2016 at 04:34 pm EDT
Share
On July 6, 2016, Agile Therapeutics, Inc. announced the appointment of Renee Selman as the Company's Chief Commercial Officer, effective July 6, 2016. Ms. Selman will succeed Katie MacFarlane, who has chosen to return to her previous role as an advisor to the Company as managing partner of SmartPharma, LLC., as of the Effective Date.
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
AGILE THERAPEUTICS, INC. 
